Abstract
Objective :
The purpose of this study was to investigate the efficacy and safety of Fixed Dose Combination (FDC) of olanzapine 5 mg and fluoxetine 20 mg in Indian patients with severe or treatment resistant depression.
Design :
This was an open, non-comparative study of seven weeks duration with an initial placebo run in period of one week.
Method :
One hundred and fifty three patients were enrolled. One hundred and forty-four patients completed the study as per protocol and 151 patients were safety evaluable. One hundred and eleven patients (77%) received one tablet of FDC of olanzapine 5 mg / fluoxetine 20 mg once daily for 6 weeks, in patients (14%), the dose was stepped up at the end of 2 weeks to 2 tablets of FDC of olanzapine 5 mg/ fluoxetine 20 mg once daily for a further 4 weeks and 13 patients (9%) required dose to be stepped up at the end of 4 weeks to 3 tablets of FDC of olanzapine 5 mg and fluoxetine 20 mg once daily for last 2 weeks.
Results :
One hundred and thirty four patients (93%) responded to FDC of olanzapine and fluoxetine therapy (a responder was defined as a patient with 50 % reduction over baseline in HDRS total score at the end of therapy).Statistically significant (p < 0.0001) reductions in HDRS total score, MADRS total score and CGI severity scores were seen with olanzapine/ fluoxetine combination. One hundred and four patients (72%) were remitters (HDRS total score of <7) after 6 weeks of therapy.
Adverse experiences were reported by thirty one patients (20.5%). Majority of them were mild in intensity. No serious adverse event was recorded with study therapy. Three patients were withdrawn from the therapy due to adverse event.
Conclusion :
Treatment with FDC of olanzapine 5 mg / fluoxetine 20 mg was highly effective and well tolerated in Indian patients with severe or treatment resistant depression.
Keywords: Olanzapine, Fluoxetine, Severe depression
Full Text
The Full Text of this article is available as a PDF (241.9 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Amsterdam J. D., Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am. 1996 Jun;19(2):371–386. doi: 10.1016/s0193-953x(05)70293-8. [DOI] [PubMed] [Google Scholar]
- Casey D. E. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiatr Clin North Am. 1993 Sep;16(3):589–610. [PubMed] [Google Scholar]
- Jeste D. V., Caligiuri M. P. Tardive dyskinesia. Schizophr Bull. 1993;19(2):303–315. doi: 10.1093/schbul/19.2.303. [DOI] [PubMed] [Google Scholar]
- Robertson M. M., Trimble M. R. Major tranquillisers used as antidepressants. A review. J Affect Disord. 1982 Sep;4(3):173–193. doi: 10.1016/0165-0327(82)90002-7. [DOI] [PubMed] [Google Scholar]
- Roose S. P., Glassman A. H., Walsh B. T., Woodring S. Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry. 1986 Mar;143(3):345–348. doi: 10.1176/ajp.143.3.345. [DOI] [PubMed] [Google Scholar]
- Rothschild A. J., Samson J. A., Bessette M. P., Carter-Campbell J. T. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry. 1993 Sep;54(9):338–342. [PubMed] [Google Scholar]
- Shelton R. C., Tollefson G. D., Tohen M., Stahl S., Gannon K. S., Jacobs T. G., Buras W. R., Bymaster F. P., Zhang W., Spencer K. A. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001 Jan;158(1):131–134. doi: 10.1176/appi.ajp.158.1.131. [DOI] [PubMed] [Google Scholar]
- Tollefson G. D., Beasley C. M., Jr, Tamura R. N., Tran P. V., Potvin J. H. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 1997 Sep;154(9):1248–1254. doi: 10.1176/ajp.154.9.1248. [DOI] [PubMed] [Google Scholar]
- Tran P. V., Dellva M. A., Tollefson G. D., Beasley C. M., Jr, Potvin J. H., Kiesler G. M. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry. 1997 May;58(5):205–211. doi: 10.4088/jcp.v58n0505. [DOI] [PubMed] [Google Scholar]
- Wolfersdorf M., Barg T., König F., Leibfarth M., Grünewald I. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry. 1995 Mar;28(2):56–60. doi: 10.1055/s-2007-979589. [DOI] [PubMed] [Google Scholar]
- Wolfersdorf M., König F., Straub R. Pharmacotherapy of delusional depression: experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol. Neuropsychobiology. 1994;29(4):189–193. doi: 10.1159/000119086. [DOI] [PubMed] [Google Scholar]